First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100

NCT05426746 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

ARDS, Human

Interventions

DRUG: ALT-100
OTHER: Normal Saline

Sponsor

Aqualung Therapeutics Corp.